Replies to post #196828 on Cytodyn Inc (CYDY)

[C-20]

It really doesn’t matter if they agree or don’t agree , wether or not it comes by the hands of CyDy or another companies work . This drug is coming to market very soon. All of the static we longs put up with on a daily basis will very soon be forgotten as this drug goes to work in a very prescribed manner on several indications. Longs do not be troubled by all the negatives you hear, I’m telling you right here and right now your patients and dedication will be rewarded!

[3X Charm]

100% failed the CoVID trials, as in did not meet any trial primary or secondary endpoints leading to a direct path to approval via EUA or BLA process.

No one and no entity who’s opinions matter regarding any approvals has accepted the post hoc data mined information as being significant enough to warrant approval.

In fact, the data appears so insignificant that the Brazil trial has only 4 patients enrolled .

Once again Nader must resort to expediency at the expense of scientific significance to try and force a result by reducing the trial size.


The CoVID trials were successful, However in proving once again that Nader is out of his league in the pharma space.

Nader, as always, tried to mislead investors with the tNBC”EUA” in Canada for one patient already receiving LL.
…but we all knew that was a lie.